{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T08:50:27Z","timestamp":1794732627830,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010062","name":"Towson University Faculty Development and Research Committee and Graduate Student Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010062","name":"Towson University Department of Biological Sciences and Department of Graduate Studies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.antiviral.2020.104754","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T02:32:05Z","timestamp":1582770725000},"page":"104754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1"],"prefix":"10.1016","volume":"176","author":[{"given":"Zachary W.","family":"Greeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Giannasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan J.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Margulies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104754_bib1","first-page":"5863","volume":"79","author":"Andrei","year":"2005"},{"key":"10.1016\/j.antiviral.2020.104754_bib2","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Prspectives Med."},{"key":"10.1016\/j.antiviral.2020.104754_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1479-5876-9-115","article-title":"Combination therapy\u00a0: the next opportunity and challenge of medicine","volume":"9","author":"Ascierto","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.antiviral.2020.104754_bib4","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1128\/JVI.77.14.7820-7829.2003","article-title":"Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids","volume":"77","author":"Bestman-Smith","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104754_bib5","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1086\/315524","article-title":"Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant Recipients\u00a0: risk factors and prognostic significance","volume":"1999","author":"Chakrabarti","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104754_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104754_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","article-title":"Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"97","author":"Chono","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104754_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1037\/a0015826","article-title":"Design of experiments with multiple indpendent variables: a resource management perspective on complete and reduced factorial dsigns","volume":"14","author":"Collins","year":"2010","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.antiviral.2020.104754_bib9","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.86.7.2186","article-title":"Herpes simplex virus 1 helicase-primase\u00a0: a complex of three herpes-encoded gene products","volume":"86","author":"Crute","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2020.104754_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of action and selectivity of acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am. J. Med."},{"key":"10.1016\/j.antiviral.2020.104754_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0030-4220(91)90188-I","article-title":"Herpes simplex virus in immunocompromised patients: growing evidence of drug resistance","volume":"72","author":"Epstein","year":"1991","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"10.1016\/j.antiviral.2020.104754_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.aca.2007.07.011","article-title":"Box-Behnken design: an alternative for the optimization of analytical methods","volume":"597","author":"Ferreira","year":"2007","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.antiviral.2020.104754_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.49.3.1055-1059.2005","article-title":"Herpes simplex virus thymidine kinase mutations associated with resistance to Acyclovir\u00a0: a site-directed mutagenesis study","volume":"49","author":"Frobert","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104754_bib14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.20.4.518","article-title":"Metabolism of acyclovir in virus-infected and uninfected cells","volume":"20","author":"Furman","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104754_bib15","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1016\/S0021-9258(17)42739-6","article-title":"Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase","volume":"259","author":"Furman","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104754_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/clpt.1992.83","article-title":"Pharmacodynamics and Drug Action: an additive or synergistic drug interaction: application of concentrations-effect modeling","volume":"51","author":"Meredith","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2020.104754_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside Analogues","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104754_bib18","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/AAC.00545-11","article-title":"CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections","volume":"55","author":"Prichard","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104754_bib19","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1016\/S0021-9258(18)83248-3","article-title":"Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate","volume":"264","author":"Reardon","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104754_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6161230","article-title":"Volatile acid-solvent evaporation (VASE): molcularly homogenous distribution of acyclovir in a bioerodable polymer matrix for long term treatment of herpes simplex virus-1 infections","volume":"2018","author":"Stegman","year":"2018","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.antiviral.2020.104754_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2020.104754_bib22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1212\/WNL.0b013e3182752ceb","article-title":"Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised","volume":"79","author":"Tan","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.antiviral.2020.104754_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/sti.2006.019935","article-title":"Genital HSV-1 infections","volume":"82","author":"Wald","year":"2006","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.antiviral.2020.104754_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/cid\/ciw219","article-title":"Management of hepatitis C\/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy","volume":"63","author":"Wyles","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104754_bib25","doi-asserted-by":"crossref","first-page":"A321","DOI":"10.1016\/0166-3542(95)94877-5","article-title":"The consequence of incorporation of (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine by human cytomegalovirus DNA polymerase on DNA elongation","volume":"26","author":"Xiong","year":"1995","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104754_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2016.12.008","article-title":"Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor","volume":"139","author":"Yajima","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104754_bib27","article-title":"Synergistic and antagonistic drug combinations depend on network topology","volume":"9","author":"Yin","year":"2014","journal-title":"PloS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930600X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421930600X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:38Z","timestamp":1759062698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421930600X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":27,"alternative-id":["S016635421930600X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104754","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104754"}}